Literature DB >> 8551103

Irradiation-enhanced binding of carboplatin to DNA.

L X Yang1, E Douple, H J Wang.   

Abstract

Carboplatin (3.6 mM) and salmon sperm DNA (3 micrograms), either double-stranded (dsDNA) or denatured single-stranded) (ssDNA), were irradiated (100 Gy) under hypoxic or oxic conditions. The drug and DNA were mixed either before, during, or after irradiation, and platinum binding to DNA was measured using atomic absorption spectrometry. Irradiation significantly increased the binding of carboplatin to dsDNA under hypoxic conditions, but did not increase the binding of carboplatin to ssDNA under similar hypoxic conditions. Irradiation did not result in an increased dsDNA-platinum binding under oxic conditions. When carboplatin was added to dsDNA immediately following irradiation of dsDNA, no increase in platinum binding was observed. When carboplatin and dsDNA were irradiated simultaneously but separately and then mixed there appears to be a slight increase in platinum binding, but it was not significant. Tetra-ammineplatinum (II) chloride, a non-cytotoxic platinum compound, did not show an increase in platinum-DNA binding following irradiation under hypoxic conditions. The results suggest that radiation-enhanced carboplatin binding to DNA might be at least partly responsible for radiosensitization by carboplatin, especially in a cell line sensitive to carboplatin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8551103     DOI: 10.1080/09553009514551611

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  2 in total

1.  Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant glioma.

Authors:  K Peterson; G Harsh; P G Fisher; J Adler; Q Le
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

2.  Carboplatin and tegafur-uracil concomitant with standard radiotherapy in the management of locally advanced head and neck cancer.

Authors:  Angel Segura Huerta; Roberto Díaz-Beveridge; José A Pérez-Fidalgo; Verónica Calderero Aragón; Miguel Pastor Borgoñón; Jorge Aparicio Urtasun; Joaquín Montalar Salcedo
Journal:  Clin Transl Oncol       Date:  2005 Jan-Feb       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.